Drug Database · Clinicians

Oxaliplatin

Brands (68) Oxaliget, Baplatin, Celdach…Show all

Platinum-based Drug US FDA class
Antineoplastic agent( platinum compound); Antineoplastic agent (platinum compund); and others PH FDA category

Rx · Prescription drug88 PH productsPNF-listedVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID a6f89dc3-a594-4b5b-8728-272e20c1ecb5, version date August 24, 2026 (Oxaliplatin · Gland Pharma Limited). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer.
  • treatment of advanced colorectal cancer.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Oxaliplatin injection, in combination with infusional fluorouracil and leucovorin, is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. treatment of advanced colorectal cancer. Oxaliplatin is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. (1) treatment of advanced colorectal cancer. (1)

Contraindications

4 CONTRAINDICATIONS Oxaliplatin is contraindicated in patients with a history of a hypersensitivity reaction to oxaliplatin or other platinum-based drugs. Reactions have included anaphylaxis [see Warnings and Precautions (5.1)]. History of hypersensitivity reaction to oxaliplatin or other platinum-based drugs. (4, 5.1)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Administer oxaliplatin injection 85 mg/m 2 as an intravenous infusion over 120 minutes concurrently with leucovorin over 120 minutes in separate bags, followed by fluorouracil on Day 1 of each 14-day cycle. Administer fluorouracil and leucovorin on Day 2 as recommended. (2.1)
  • Adjuvant Treatment: Continue treatment for up to 12 cycles or unacceptable toxicity. (2.1)
  • Advanced Colorectal Cancer: Continue treatment until disease progression or unacceptable toxicity. (2.1)
2.1 Recommended Dosage

2.1 Recommended Dosage Administer oxaliplatin injection in combination with fluorouracil and leucovorin every 2 weeks.

  • For adjuvant treatment, continue treatment for up to 12 cycles or unacceptable toxicity.
  • For advanced colorectal cancer, continue treatment until disease progression or unacceptable toxicity. Day 1 Administer oxaliplatin injection 85 mg/m 2 as an intravenous infusion over 120 minutes and leucovorin 200 mg/m 2 as an intravenous infusion over 120 minutes at the same time in separate bags, followed by fluorouracil 400 mg/m 2 as intravenous bolus over 2 to 4 minutes, followed by fluorouracil 600 mg/m 2 as a 22-hour continuous infusion. Day 2 Administer leucovorin 200 mg/m 2 as an intravenous infusion over 120 minutes, followed by fluorouracil 400 mg/m 2 as intravenous bolus over 2 to 4 minutes, followed by fluorouracil 600 mg/m 2 as a 22-hour continuous infusion. Refer to the prescribing information for fluorouracil and leucovorin for additional information.
2.2 Dose Modifications for Adverse Reactions

2.2 Dose Modifications for Adverse Reactions Prolongation of infusion time for oxaliplatin injection from 2 hours to 6 hours may mitigate acute toxicities, such as non-life-threatening infusion-related reactions. Permanently discontinue oxaliplatin injection for any of the following:

  • Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
  • Posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions (5.4)]
  • Confirmed interstitial lung disease or pulmonary fibrosis [see Warnings and Precautions (5.5)]
  • Rhabdomyolysis [see Warnings and Precautions (5.8)] Refer to the fluorouracil and leucovorin prescribing information for dosage modifications for adverse reactions. Dosage Modifications for Adjuvant Treatment Dosage modifications for adverse reactions for adjuvant treatment are presented in Table 1. Table 1: Dosage Modifications for Adjuvant Treatment in Patients with Stage III Colon Cancer Adverse Reactions Severity Oxaliplatin Injection Dosage Modifications Peripheral Sensory Neuropathy [see Warnings and Precautions (5.2)] Persistent Grade 2 Consider reducing oxaliplatin injection dose to 75 mg/m 2. Persistent Grade 3 Consider discontinuing oxaliplatin injection. Grade 4 Discontinue oxaliplatin injection. Myelosuppression [see Warnings and Precautions (5.3), Adverse Reactions (6.1)]. Grade 4 neutropenia or febrile neutropenia Delay the next dose until neutrophils greater than or equal to 1.5 × 10 9 /L and platelets greater than or equal to 75 × 10 9 /L. Reduce oxaliplatin injection dose to 75 mg/m 2. Grade 3 to 4 thrombocytopenia Gastrointestinal Adverse Reactions [see Adverse Reactions (6.1)] Grade 3 to 4 After recovery, reduce oxaliplatin injection dose to 75 mg/m 2 along with a dose reduction of fluorouracil to 300 mg/m 2 as an intravenous bolus and 500 mg/m 2 as a 22-hour continuous infusion. Dosage Modifications for Advanced Colorectal Cancer Dosage modifications for adverse reactions for advanced colorectal cancer are presented in Table 2. Table 2: Dosage Modifications for Advanced Colorectal Cancer Adverse Reactions Severity Oxaliplatin Injection Dosage Modifications Neuropathy [see Warnings and Precautions (5.2)] Persistent Grade 2 Consider reducing oxaliplatin injection dose to 65 mg/m 2. Persistent Grade 3 Consider discontinuing oxaliplatin injection. Grade 4 Discontinue oxaliplatin injection. Myelosuppression [see Warnings and Precautions (5.3), Adverse Reactions (6.1)] Grade 4 neutropenia or febrile neutropenia Delay the next dose until neutrophils greater than or equal to 1.5 × 10 9 /L and platelets greater than or equal to 75 × 10 9 /L. Reduce oxaliplatin injection dose to 65 mg/m 2. Grade 3 to 4 thrombocytopenia Gastrointestinal Adverse Reactions [see Adverse Reactions (6.1)] Grade 3 to 4 After recovery, reduce oxaliplatin injection dose to 65 mg/m 2 along with a dose reduction of fluorouracil to 300 mg/m 2 as an intravenous bolus and 500 mg/m 2 as a 22-hour continuous infusion.
2.3 Dose Modifications for Patients with Renal Impairment

2.3 Dose Modifications for Patients with Renal Impairment In patients with severe renal impairment (creatinine clearance [CLcr] less than 30 mL/min, calculated by the Cockcroft-Gault equation), reduce the oxaliplatin injection dose to 65 mg/m 2 [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].

2.4 Preparation and Administration

2.4 Preparation and Administration Oxaliplatin is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Do not freeze. Protect the concentrated solution from light. Dilute concentrated solution with 250 to 500 mL of 5% Dextrose Injection, USP. Do not dilute with sodium chloride solution or other chloride-containing solutions.

Store diluted solution for no more than 6 hours at room temperature (20°C to 25°C [68°F to 77°F]) or 24 hours under refrigeration (2°C to 8°C [36°F to 46°F]). Protection from light is not required. Visually inspect for particulate matter and discoloration prior to administration and discard if present. Do not mix oxaliplatin injection or administer oxaliplatin injection through the same infusion line concurrently with alkaline medications or media (such as basic solutions of fluorouracil).

Flush the infusion line with 5% Dextrose Injection, USP prior to administration of any concomitant medication. Do not use needles or intravenous administration sets containing aluminum parts for the preparation or mixing of oxaliplatin injection. Aluminum has been reported to cause degradation of platinum compounds. Administer oxaliplatin injection as an intravenous infusion over 120 minutes concurrently with leucovorin over 120 minutes in separate bags.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, use in specific populations)

2.3 Dose Modifications for Patients with Renal Impairment In patients with severe renal impairment (creatinine clearance [CLcr] less than 30 mL/min, calculated by the Cockcroft-Gault equation), reduce the oxaliplatin injection dose to 65 mg/m 2 [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].

8.6 Patients with Renal Impairment The AUC of unbound platinum in plasma ultrafiltrate was increased in patients with renal impairment [see Clinical Pharmacology (12.3)]. No dose reduction is recommended for patients with mild (creatinine clearance 50 to 79 mL/min) or moderate (creatinine clearance 30 to 49 mL/min) renal impairment, calculated by Cockcroft-Gault equation. Reduce the dose of oxaliplatin in patients with severe renal impairment (creatinine clearance less than 30 mL/min) [see Dosage and Administration (2.3)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of oxaliplatin in pediatrics have not been established. Safety and effectiveness were assessed across 4 open-label studies in 235 patients aged 7 months to 22 years with solid tumors. In a multicenter, open-label, non-comparative, non-randomized study (ARD5531), oxaliplatin was administered to 43 patients with refractory or relapsed malignant solid tumors, mainly neuroblastoma and osteosarcoma.

The dose limiting toxicity (DLT) was sensory neuropathy at a dose of 110 mg/m 2. The main adverse reactions were: paresthesia (60%, grade 3 to 4: 7%), fever (40%, grade 3 to 4: 7%), and thrombocytopenia (40%, grade 3 to 4: 27%). No responses were observed. In an open-label non-randomized study (DFI7434), oxaliplatin was administered to 26 pediatric patients with metastatic or unresectable solid tumors, mainly neuroblastoma and ganglioneuroblastoma.

The DLT was sensory neuropathy at a dose of 160 mg/m 2. No responses were observed. In an open-label, single-agent study (ARD5021), oxaliplatin was administered to 43 pediatric patients with recurrent or refractory embryonal CNS tumors. The most common adverse reactions reported were: leukopenia (67%, grade 3 to 4: 12%), anemia (65%, grade 3 to 4: 5%), thrombocytopenia (65%, grade 3 to 4: 26%), vomiting (65%, grade 3 to 4: 7%), neutropenia (58%, grade 3 to 4: 16%), and sensory neuropathy (40%, grade 3 to 4: 5%).

In an open-label single-agent study (ARD5530), oxaliplatin was administered to 123 pediatric patients with recurrent solid tumors, including neuroblastoma, osteosarcoma, Ewing sarcoma or peripheral PNET, ependymoma, rhabdomyosarcoma, hepatoblastoma, high grade astrocytoma, brain stem glioma, low grade astrocytoma, malignant germ cell tumor and other tumors. The most common adverse reactions reported were: sensory neuropathy (52%, grade 3 to 4: 12%), thrombocytopenia (37%, grade 3 to 4: 17%), anemia (37%, grade 3 to 4: 9%), vomiting (26%, grade 3 to 4: 4%), increased ALT (24%, grade 3 to 4: 6%), increased AST (24%, grade 3 to 4: 2%), and nausea (23%, grade 3 to 4: 3%).

The pharmacokinetic parameters of ultrafiltrable platinum were evaluated in 105 pediatric patients during the first cycle. The mean clearance in pediatric patients estimated by the population pharmacokinetic analysis was 4.7 L/h (%CV, 41%). Mean platinum pharmacokinetic parameters in ultrafiltrate were Cmax of 0.75 ± 0.24 mcg/mL, AUC0-48h of 7.52 ± 5.07 mcg∙h/mL and AUCinf of 8.83 ± 1.57 mcg.h/mL at 85 mg/m 2 of oxaliplatin and Cmax of 1.10 ± 0.43 mcg/mL, AUC0-48h of 9.74 ± 2.52 mcg.h/mL and AUCinf of 17.3 ± 5.34 mcg.h/mL at 130 mg/m 2 of oxaliplatin.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use In the adjuvant treatment trial [see Clinical Studies (14.1)], 400 patients who received oxaliplatin with fluorouracil/leucovorin were greater than or equal to 65 years. The effect of oxaliplatin in patients greater than or equal to 65 years was not conclusive. Patients greater than or equal to 65 years receiving oxaliplatin experienced more diarrhea and grade 3 to 4 neutropenia (45% vs 39%) compared to patients less than 65 years.

In the previously untreated advanced colorectal cancer trial [see Clinical Studies (14.2)], 99 patients who received oxaliplatin with fluorouracil and leucovorin were greater than or equal to 65 years. The same efficacy improvements in response rate, time to tumor progression, and overall survival were observed in the greater than or equal to 65 years patients as in the overall study population.

Adverse reactions were similar in patients less than 65 and greater than or equal to 65 years, but older patients may have been more susceptible to diarrhea, dehydration, hypokalemia, leukopenia, fatigue, and syncope. In the previously treated advanced colorectal cancer trial [see Clinical Studies (14.3)], 55 patients who received oxaliplatin with fluorouracil and leucovorin were greater than or equal to 65 years.

No overall differences in effectiveness were observed between these patients and younger adults. Adverse reactions were similar in patients less than 65 and greater than or equal to 65 years, but older patients may have been more susceptible to diarrhea, dehydration, hypokalemia, and fatigue. No significant effect of age on the clearance of ultrafiltrable platinum has been observed [see Clinical Pharmacology (12.3)].

Administration

2.2 Dose Modifications for Adverse Reactions Prolongation of infusion time for oxaliplatin injection from 2 hours to 6 hours may mitigate acute toxicities, such as non-life-threatening infusion-related reactions. Permanently discontinue oxaliplatin injection for any of the following: • Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] • Posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions (5.4) ] • Confirmed interstitial lung disease or pulmonary fibrosis [see Warnings and Precautions (5.5) ] • Rhabdomyolysis [see Warnings and Precautions (5.8) ] Refer to the fluorouracil and leucovorin prescribing information for dosage modifications for adverse reactions. Dosage Modifications for Adjuvant Treatment Dosage modifications for adverse reactions for adjuvant treatment are presented in Table 1. Table 1: Dosage Modifications for Adjuvant Treatment in Patients with Stage III Colon Cancer Adverse Reactions Severity Oxaliplatin Injection Dosage Modifications Peripheral Sensory Neuropathy [see Warnings and Precautions (5.2) ] Persistent Grade 2 Consider reducing oxaliplatin injection dose to 75 mg/m 2 . Persistent Grade 3 Consider discontinuing oxaliplatin injection. Grade 4 Discontinue oxaliplatin injection. Myelosuppression [see Warnings and Precautions (5.3) , Adverse Reactions (6.1) ]. Grade 4 neutropenia or febrile neutropenia Delay the next dose until neutrophils greater than or equal to 1.5 × 10 9 /L and platelets greater than or equal to 75 × 10 9 /L. Reduce oxaliplatin injection dose to 75 mg/m 2 . Grade 3 to 4 thrombocytopenia Gastrointestinal Adverse Reactions [see Adverse Reactions (6.1) ] Grade 3 to 4 After recovery, reduce oxaliplatin injection dose to 75 mg/m 2 along with a dose reduction of fluorouracil to 300 mg/m 2 as an intravenous bolus and 500 mg/m 2 as a 22-hour continuous infusion. Dosage Modifications for Advanced Colorectal Cancer Dosage modifications for adverse reactions for advanced colorectal cancer are presented in Table 2. Table 2: Dosage Modifications for Advanced Colorectal Cancer Adverse Reactions Severity Oxaliplatin Injection Dosage Modifications Neuropathy [see Warnings and Precautions (5.2) ] Persistent Grade 2 Consider reducing oxaliplatin injection dose to 65 mg/m 2 . Persistent Grade 3 Consider discontinuing oxaliplatin injection. Grade 4 Discontinue oxaliplatin injection. Myelosuppression [see Warnings and Precautions (5.3) , Adverse Reactions (6.1) ] Grade 4 neutropenia or febrile neutropenia Delay the next dose until neutrophils greater than or equal to 1.5 × 10 9 /L and platelets greater than or equal to 75 × 10 9 /L. Reduce oxaliplatin injection dose to 65 mg/m 2 . Grade 3 to 4 thrombocytopenia Gastrointestinal Adverse Reactions [see Adverse Reactions (6.1) ] Grade 3 to 4 After recovery, reduce oxaliplatin injection dose to 65 mg/m 2 along with a dose reduction of fluorouracil to 300 mg/m 2 as an intravenous bolus and 500 mg/m 2 as a 22-hour continuous infusion.

2.4 Preparation and Administration Oxaliplatin is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Do not freeze. Protect the concentrated solution from light. Dilute concentrated solution with 250 to 500 mL of 5% Dextrose Injection, USP. Do not dilute with sodium chloride solution or other chloride-containing solutions. Store diluted solution for no more than 6 hours at room temperature (20°C to 25°C [68°F to 77°F]) or 24 hours under refrigeration (2°C to 8°C [36°F to 46°F]). Protection from light is not required. Visually inspect for particulate matter and discoloration prior to administration and discard if present. Do not mix oxaliplatin injection or administer oxaliplatin injection through the same infusion line concurrently with alkaline medications or media (such as basic solutions of fluorouracil). Flush the infusion line with 5% Dextrose Injection, USP prior to administration of any concomitant medication. Do not use needles or intravenous administration sets containing aluminum parts for the preparation or mixing of oxaliplatin injection. Aluminum has been reported to cause degradation of platinum compounds. Administer oxaliplatin injection as an intravenous infusion over 120 minutes concurrently with leucovorin over 120 minutes in separate bags.

US FDA label

Dosage forms

Philippines

  • ) solution for injection: 2 mg/mL (100 mg/5 mL, 2 mg/mL (100 mg/50 mL, 2 mg/mL (50 mg/25 mL, 5 mg/mL (100 mg/20 mL, 5 mg/mL (50 mg/10 mL, 5 mg/mL (50 mg/mL
  • ) concentrate solution for iv infusion: 2 mg/mL (100 mg/5 mL, 2 mg/mL (100 mg/50 mL, 2 mg/mL (50 mg/25 mL
  • Lyophilized powder for injection: 50 mg, 100 mg
  • Lyophilized powder for iv infusion: 50 mg
  • ) solution for iv infusion: 2 mg/mL (100 mg/50 mL, 2 mg/mL (50 mg/25 mL, 5 mg/mL (50 mg/10 mL) and (100 mg/20 mL
  • Concentrate solution for injection: 2 mg/mL
  • Powder for solution for iv infusion: 50 mg, 100 mg
  • ) concentrate solution for i.v. infusion: 5 mg/mL (100 mg/20 mL, 5 mg/mL (50 mg/10 mL
  • Concentrate for solution for infusion: 5 mg/mL
  • Lyophilized powder for injection for i.v. infusion: 50 mg, 100 mg

and 16 more forms; see the products table.

Registered products in the Philippines

88 products registered with the Food and Drug Administration (FDA) Philippines list Oxaliplatin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products88
Philippine FDA-registered products for Oxaliplatin
Package insert
Aplixatin-100Oxaliplatin
2 mg/mL (100mg/50 mL) Concentrate Solution for IV Infusion50 mL-capacity USP Type I Amber Glass Vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Detoxicare Phils., Inc.Importer: Ambica International Corporation
DRP-10165
Oct 20, 2031
Aplixatin-50Oxaliplatin
2 mg/mL (50mg/25 mL) Concentrate Solution for IV Infusion30 mL-capacity USP Type I Amber Glass Vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Detoxicare Phils., Inc.Importer: Ambica International Corporation
DRP-10166
Oct 6, 2031
BaplatinOxaliplatin
100 mg Lyophilized Powder for Solution for Infusion (IV)50 mL USP Type II amber glass vial with halobutyl rubber stopper and white flip-off aluminium seal Box of 1's
RxVAT-exempt
Laboratorio Kemex S.A.Argentine Republic
Apolloplus Capital Inc.Trader: Bioprofarma Bago S.A.
DR-XY46429
Sep 28, 2028
BaplatinOxaliplatin
50 mg Lyophilized Powder for Solution for Infusion (IV)25 mL USP Type I amber glass vial with halobutyl rubber stopper and royal-blue flip-off aluminium seal (Box of 1's)
RxVAT-exempt
Laboratorio Kemex S.A.Argentine Republic
Apolloplus Capital Inc.Trader: Bioprofarma Bago S.A.
DR-XY46428
Sep 28, 2028
CeldachOxaliplatin
100 mg Lyophilized Powder for solution for I.V InfusionUSP Type I Clear Glass Vial with Grey Bromobutyl Rubber Stopper with Red Color Flip-off seal x 50 mL (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E Medica Inc.
DRP-2367
Jul 30, 2030
CeldachOxaliplatin
50mg Lyophilized Power for Solution for I.V InfusionUSP Type I Clear tubular glass vial with grey bromobutyl rubber stopper with red color flip-off seal x 30mL (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E. Medica, Inc.
DRP-2365
Jul 30, 2031
ColorebeneOxaliplatin
100 mg Lyophilized Powder for Solution for I.V. InfusionUSP Type I Clear Glass Vial with Grey Bromobutyl Rubber Stopper with Red Color Flip-off Seal x 50 mL (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix, Inc.Importer: I.E Medica Inc.
DRP-2367-01
Feb 20, 2031
ColorebeneOxaliplatin
50 mg Lyophilized Powder for Solution for I.V. InfusionUSP Type l Clear Tubular Glass Vial with Grey Bromobutyl Rubber Stopper with Red Color Flip-off Seal x 30 mL (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix, Inc.Importer: I.E Medica Inc.
DRP-2365-01
Jun 13, 2031
ColoxOxaliplatin
50 mg Lyophilized Powder for Injection (IV Infusion)30 mL-capacity Type I glass vial with gray bromobutyl rubber stopper and blue aluminum-plastic flip-off cap (Box of 1's)
RxVAT-exempt
Cisen Pharmaceutical Co. Ltd.China
Macropharma Corporation
DRP-15871
Sep 25, 2029
ColoxatinOxaliplatin
100 mg Lyophilized Powder for Injection (I.V. Infusion)USP Type I clear colorless glass vial (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals Ltd.India
Accord Healthcare Limited - Philippine Branch OfficeImporter: Oncolife Corporation
DRP-7193-01
Jan 19, 2027
DoxatinOxaliplatin
50 mg Lyophilized Powder for Injection (IV Infusion)30 mL-capacity colorless transparent borosilicate glass vial sealed with rubber stopper and blue aluminum plastic cap (1 vial/box; each carton contains 100 boxes)
RxVAT-exempt
Cisen Pharmaceutical Co., Ltd.China
Endure Medical, Inc.
DR-XY48985
Jan 25, 2029
EloxaOxaliplatin
5mg/ mL (50 mg/10 mL & 100 mg/20 mL) Concentrate For Solution For I.V. InfusionUSP Type I Clear Glass Vial with Bromo butyl Rubber Stopper and Flip- off Aluminum Seal Cap x 10 mL & 20 mL (Box of 1's)
RxVAT-exempt
Qilu Pharmaceutical (Hainan) Co. Ltd.China
Macropharma Corporation
DRP-18407
Jul 2, 2031
EloxatinOxaliplatin
5 mg/mL Concentrate for Solution for Infusion (IV)Type I Colorless Glass Vial x 10 mL (equivalent to 50 mg) Box of 1's; Type I Colorless Glass Vial x 20 mL (equivalent to 100 mg) Box of 1's; Type I Colorless Glass Vial x 40 mL (equivalent to 200 mg) Box of 1's
RxVAT-exempt
Sanofi-Aventis Deutschland GmbHGermany
Importer: Sanofi-Aventis Philippines Inc.
DR-XY32998
Oct 9, 2029
Emiplatin-100Oxaliplatin
2 mg/mL (100 mg/50 mL) Solution for Injection (IV Infusion)USP Type I Amber Glass Vial x 50 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp.
DRP-8426-04
Sep 13, 2028
Emiplatin-50Oxaliplatin
2 mg / mL (50 mg/ 25 mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 30 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp.
DRP-8699-04
Sep 12, 2028
Fin- Oxali 50Oxaliplatin
5 mg/mL (50 mg/10 mL) Solution for Injection (I.V.)10 mL-net content USP Type I amber glass vial with bromobutyl rubber plug and aluminum seal polypropylene flip-off cap (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
Finstad, Inc.
DRP-14908
Feb 7, 2029
FlucinOxaliplatin
100 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11224-01
Feb 15, 2027
FlucinOxaliplatin
50 mg Lyophilized Powder for IV Infusion50 mL USP Type I Clear Glass Vial with Gray Bromo Butyl Rubber Stopper, Aluminum Cap and Blue Flip-off Seal (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11004-01
Dec 31, 2026
GenplatinOxaliplatin
100 mg Lyophilized Powder for Injection (IV Infusion)50mL Type I Transparent Colorless Glass Vial Sealed with Gray Rubber Stopper and Aluminum Seal with PP Cap x 1's (Box of 1's)
RxVAT-exempt
Chong Kun Dang Pharmaceutical Corp.Republic of Korea
GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc
DRP-12596-01
Sep 12, 2027
HenplatinOxaliplatin
50 mg Lyophilized Powder for Injection (IV)USP Type I Neutral Borosilicate Glass Vial with 20 mm Rubber Stopper and Aluminum Plastic Cap x 20 mL (Box of 1’s)
RxVAT-exempt
Jiangsu-Hengrui Pharmaceutical Co., Ltd.China
Goodfellow Pharma Corporation
DR-XY32620
Jun 9, 2037
InnoxaplinOxaliplatin
2 mg/mL (50 mg/25 mL) Concentrate Solution for IV Infusion30 mL-capacity USP Type I Amber Moulded Glass Vial x 25 mL with Bromobutyl Rubber Stopper and Green Flip-off Seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Innocure Pharma and Medical Supplies TradingImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8887-01
Jul 2, 2030
Innoxaplin 100Oxaliplatin
2 mg/mL (100 mg/5 mL) Concentrate Solution for IV InfusionUSP Type I Amber Molded Glass Vial x 50 mL with bromobutyl rubber stopper and green flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Innocure Pharma and Medical Supplies TradingImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8888-01
Jul 2, 2030
LealoxaliOxaliplatin
2 mg / mL (50 mg / 25 mL) Concentrate Solution for IV Infusion30 mL-capacity USP Type I Amber Glass Vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Lealmeds Pharmaceutical Inc.Importer: Ambica International Corporation
DRP-10166-02
Oct 6, 2031
LealoxaliOxaliplatin
2 mg/mL (100mg/50 mL) Concentrate Solution for IV Infusion50 mL-capacity USP Type I Amber Glass Vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Lealmeds Pharmaceutical Inc.Importer: Ambica International Corporation
DRP-10165-02
Oct 6, 2031
LipanoxOxaliplatin
2 mg/mL Concentrate Solution for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 10 mL and 20 mL (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Kaufmann Pharma Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11225-01
Feb 15, 2027
MeslatinOxaliplatin
100 mg Lyophilized Powder for Injection (I.V. Infusion)USP Type I Clear Colorless Glass Vial (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Oncolife Corporation
DR-XY40552
Jan 19, 2027
MeslatinOxaliplatin
50 mg Lyophilized Powder for Injection (IV Infusion)USP Type I Clear Colorless Glass Vial (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Oncolife Corporation
DRP-8219
Jan 24, 2027
NoneOxaliplatin
2 mg/mL (100 mg/50 mL) Solution for Injection (IV)Type I Amber Moulded Glass Vial x 50 mL (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-5174-01
Feb 13, 2029
NoneOxaliplatin
5 mg/mL (100mg/20mL) Solution for Injection (IV Infusion)20 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and flip-off cap (Box of 1's)
RxVAT-exempt
Alwin DMD PharmaceuticalsIndia
Amediqo Phils., Inc.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-15506-01
Jul 30, 2029
NoneOxaliplatin
5 mg/mL Concentrate for Solution for IV InfusionUSP Type I Clear Glass Vial x 10 mL and 20 mL with rubber stopper and green (for 10 mL) or dark blue (for 20 mL) flip-off seal (Box of 1's)
RxVAT-exempt
Zydus Hospira Oncology Pvt. Ltd.India
Importer: Pfizer, Inc.
DR-XY45870
May 9, 2027
NovaplatinOxaliplatin
100 mg Lyophilized Powder for Injection (IV Infusion)50 mL Type I Transparent Colorless Glass Vial Sealed with Gray Rubber Stopper and Aluminum Seal with PP Cap x l's (Box of 1's)
RxVAT-exempt
Chong Kun Dang Pharmaceutical Corp.Korea
Medinova Pharmaceutical, Inc.
DRP-12596
Sep 12, 2027
NovaplatinOxaliplatin
50 mg Lyophilized Powder for Injection (IV Infusion)40 mL-capacity Type I Clear and Colorless Glass Vial Sealed with Grey Rubber Stopper, Aluminum Seal and Green Polypropylene Flip-off Cap x 1's (Box of 1's)
RxVAT-exempt
Chong Kun Dang Pharmaceutical Corp.Korea
Medinova Pharmaceutical Inc.
DRP-17072
Sep 19, 2030
Oxa-Health 100Oxaliplatin
2 mg/mL (100 mg/50 mL) Solution for Injection (IV Infusion)USP Type I Amber Glass Vial x 50 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp.
DRP-8426-01
Sep 13, 2028
Oxa-Health 50Oxaliplatin
2 mg/mL (50 mg/25 mL) Solution for InjectionUSP Type I Amber Glass Vial x 30 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp.
DRP-8699-01
Sep 12, 2028
OxadexcelOxaliplatin
100 mg Powder for Solution for IV Infusion50 mL amber vial with elastomeric rubber stopper and aluminum crimp cap with plastic flip-off (Box of 1's)
RxVAT-exempt
Glenmark Generics S.A.Argentine Republic
One Dexcel Pharma Inc.Importer: Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Limited
DRP-8101-01
Sep 23, 2037
OxadexcelOxaliplatin
50 mg Powder for Solution for IV Infusion25 mL amber vial with elastomeric rubber stopper and aluminum crimp cap with plastic flip-off (Box of 1's)
RxVAT-exempt
Glenmark Generics S.A.Argentine Republic
One Dexcel Pharma, Inc.Importer: Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Limited
DRP-8102-01
Oct 26, 2037
OXAL SPAL-L 100Oxaliplatin
5 mg/mL (100 mg/20 mL) Solution For InfusionUSP Type I clear and colorless glass vial with grey chlorobutyl rubber stopper and parrot green aluminum- polypropylene flip-off seal x 20 mL (Box of 1's)
RxVAT-exempt
SP Accure Labs Pvt. Ltd.India
Hexagon Pharmaceuticals
DRP-15869
Sep 25, 2029
OxaleeOxaliplatin
100 mg Lyophilized Powder for I.V. InfusionType I Clear Colorless Glass Vial (Box of 1's)
RxVAT-exempt
Laboratorios Richmond S.A.C.I.F.Argentine Republic
UNILAB, Inc.
DR-XY40362
Nov 29, 2031
OxaleeOxaliplatin
50 mg Lyophilized Powder For IV InfusionType I Clear Colorless Glass Vial (Box of 1's)
RxVAT-exempt
Laboratorios Richmond S.A.C.I.F.Argentina
UNILAB, Inc.
DR-XY40361
Nov 29, 2026
OxalibilOxaliplatin
5 mg/ mL (100 mg/20 mL) Concentrate for Solution for Intravenous (IV) InfusionUSP Type I clear glass vial x 20 mL (Box of l's)
RxVAT-exempt
SP Accure Labs Pvt. Ltd.India
Hexagon Pharmaceuticals
DR-XY48264
Aug 9, 2027
OxalidexOxaliplatin
5 mg/mL Concentrate for Solution for InfusionType I Colorless Glass Vial with Grey Halobutyl Rubber Stopper and Aluminum Crimp Cap (10 mL; 20 mL; 40 mL) (Box of 1's)
RxVAT-exempt
Fareva Unterach GmbHAustria
Delex Pharma International, Inc.Importer: Sandoz Philippines Corporation
DRP-8254-01
Jul 16, 2029
OxaligetOxaliplatin
2 mg/mL (100 mg/50 mL) Solution for IV InfusionType I Amber glass vial x 50 mL with rubber stopper and aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
2mg Incorporated
DRP-16259
Jan 10, 2030
OxaligetOxaliplatin
2 mg/mL (100mg/50 mL) Concentrate Solution for IV Infusion50 mL-capacity USP Type I Amber Glass Vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
2MG IncorporatedImporter: Ambica International Corporation
DRP-10165-01
Oct 20, 2037
OxaligetOxaliplatin
2 mg/mL (50 mg/25 mL) Solution for IV Infusion.Type I amber glass vial x 25 mL in 30 mL with rubber. stopper and aluminum black flip-off seal (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
2MG Incorporated
DRP-15430
Jul 8, 2029
OxaliGetOxaliplatin
2 mg/mL (50mg/25 mL) Concentrate Solution for IV Infusion30 mL-capacity USP Type I Amber Glass Vial with bromobutyl rubber stopper and green aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
2MG IncorporatedImporter: Ambica International Corporation
DRP-10166-01
Sep 12, 2037
OxaliplaceenOxaliplatin
2 mg / mL (50 mg/25 mL) Concentrate Solution for IV InfusionUSP Type I Amber glass vial with bromobutyl rubber stopper and green flip-off seal x 25 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Noble Pharma Inc.Importer: AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Private Limited
DRP-11973-02
May 26, 2027
OxaliqoOxaliplatin
5 mg / mL (50 mg / mL) Solution for Injection (IV Infusion)10 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's)
RxVAT-exempt
Alwin DMD PharmaceuticalsIndia
Amediqo Phils., Inc.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-15507-01
Jul 30, 2029
Oxalis 100Oxaliplatin
5 mg/mL (100 mg/20mL) Solution for Injection (IV Infusion)20 mL USP type I amber glass vial with grey bromobutyl rubber stopper, aluminum seal and flip-off cap (Box of 1's)
RxVAT-exempt
Alwin DMD PharmaceuticalsIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-15506
Jul 30, 2029
Oxalis 50Oxaliplatin
5 mg/mL (50 mg/10mL) Solution for Injection (IV Infusion)10 mL USP type I amber glass vial with vial with bromobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 1's)
RxVAT-exempt
Alwin DMD PharmaceuticalsIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-15507
Jul 30, 2029
OxalitinOxaliplatin
5 mg/mL Solution for Injection for IV use10 mL USP Type I colorless glass vial Box of 1's and 10's; 20 mL USP Type I colorless glass vial Box of 1's and 10's
RxVAT-exempt
Boryung Pharamaceutical Co., Ltd.Republic of Korea
Endure Medical Inc.
DR-XY46143
Nov 2, 2027
Oxalivid 100Oxaliplatin
100 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I Colorless glass vial with 20 mm brominated butyl rubber stopper and blue 20 mm aluminum plastic cap Box of 1's
RxVAT-exempt
Qilu Pharmaceutical (Hainan) Co., Ltd.China
Hovid, Inc.Trader: Hovid Bhd.
DR-XY47098
Oct 28, 2030
Oxalivid 50Oxaliplatin
50 mg Lyophilized Powder for Injection for IV InfusionUSP Type I Colorless Glass Vial with 20 mm Brominated Butyl Rubber Stopper and Blue 20 mm Aluminum Plastic Cap (Box of 1's)
RxVAT-exempt
Qilu Pharmacetical Hainan Co., Ltd.China
Hovid Inc.Importer: Hovid IncTrader: Hovid Bhd.
DR-XY47099
Oct 29, 2030
Oxalotin 50Oxaliplatin
50 mg Lyophilized Powder for IV InfusionUSP Type I Clear Glass Vial x 50 mL Box of 1's
RxVAT-exempt
TECHNO DRUGS LIMITEDBangladesh
BRIDGEMARK MARKETING
DR-XY43225
Feb 25, 2028
OxaltinOxaliplatin
5 mg/mL (50 mg/10 mL and 100 mg/20 mL) Concentrate Solution for Intravenous InjectionUSP Type I clear and colorless glass vial x 10 mL and 20 mL (Box of 1’s)
RxVAT-exempt
Jiangsu Hengrui Pharmaceuticals Co., Ltd.China
Phil. Pharmawealth, Inc.
DR-XY47591
Dec 9, 2031
OxambaOxaliplatin
50 mg Lyophilized Powder for IV Infusion30 mL-capacity USP Type I clear glass vial, with grey butyl rubber stopper, aluminum seal, and flip-off cap (Box of 1's)
RxVAT-exempt
Cisen Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-16119
Nov 6, 2029
Oxanish-100Oxaliplatin
2 mg/mL (100 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Amber Glass Vial x 50 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Pharmastar Int'l Trading Corp.
DRP-8426
Sep 13, 2028
Oxanish-50Oxaliplatin
2 mg/mL (50mg/25mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 30 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Pharmastar Int'l Trading Corp.
DRP-8699
Sep 12, 2028
OxaplatOxaliplatin
50 mg. Lyophilized Powder for Injection (I.V. Infusion)USP Type I Amber Glass Bottle (Box of 1's)
RxVAT-exempt
Eriochem S.A.Argentina
Importer: Globo Asiatico Enterprises, Inc.
DR-XY34088
Dec 27, 2027
OxariOxaliplatin
2 mg / mL (50 mg / 25 mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 30 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Oncotine Pharmaceutical Products DistributionImporter: Pharmastar Int'l Trading Corp.
DRP-8699-03
Sep 12, 2028
OxasaphOxaliplatin
50 mg Lyophilized Powder for IV Infusion50 mL USP Type I clear glass vial with gray bromo butyl rubber stopper, aluminum cap and blue flip-off seal (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, IncTrader: Sapphire Lifesciences Pvt. Ltd.
DRP-11004
Dec 31, 2026
Oxasaph-100Oxaliplatin
100 mg Lyophilized Powder for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 1's (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11224
Feb 15, 2027
Oxasaph-2Oxaliplatin
2 mg/mL Concentrate Solution For Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 10 mL, 20 mL, 25 mL and 50 mL (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11225
Dec 27, 2027
OxawindOxaliplatin
2 mg/mL (100mg/50mL) Solution for Injection (IV Infusion)USP Type I Amber Glass Vial x 50 mL (Box of 1's)
RxVAT-exempt
ADMAC LifesciencesIndia
Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp.
DRP-8426-03
Sep 13, 2028
OxawindOxaliplatin
2 mg/mL (50 mg/25 mL) Solution for Injection (IV)USP Type I Amber Glass Vial x 30 mL (Box of 1's)
RxVAT-exempt
ADMAC LifesciencesIndia
Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp.
DRP-8699-02
Sep 12, 2028
OxAyos-100Oxaliplatin
2 mg/mL (100 mg/50 mL) Solution for IV InfusionType I amber glass vial x 50 mL with rubber stopper and aluminum flip-off seal (Box of 1’s)
RxVAT-exempt
Venus Remedies, LimitedIndia
Getmeds Philippines Inc.Importer: 2mg Incorporated
DRP-16259-01
Jan 10, 2030
OxAyos-50Oxaliplatin
2 mg/mL (50 mg/25mL) Solution for IV InfusionType I amber glass vial x 25 mL in 30 mL with rubber stopper and aluminum black flip-off seal (Box of 1’s)
RxVAT-exempt
Venus Remedies, LimitedIndia
Getmeds Philippines Inc.Importer: 2mg Incorporated
DRP-15430-01
Jul 8, 2029
OxitelOxaliplatin
5 mg/mL (50 mg/10 mL) and (100 mg/20 mL) Solution for IV Infusion10 mL (net content) USP Type I clear and colorless glass vial (Box of 1 vial); 20 mL (net content) USP Type I clear and colorless glass vial (Box of 1 vial)
RxVAT-exempt
Fresenius Kabi Oncology LimitedIndia
Fresenius Kabi Philippines Inc.
DR-XY47603
Dec 13, 2028
OxubaOxaliplatin
100 mg Powder for Solution for IV Infusion50 mL amber vial with elastomeric rubber stopper and aluminum crimp cap with plastic flip-off Box of 1's
RxVAT-exempt
Glenmark Generics S.A.Argentine Republic
Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Limited
DRP-8101
Mar 16, 2037
OxubaOxaliplatin
50 mg Powder for Solution for IV Infusion25 mL amber vial with elastomeric rubber stopper and aluminum crimp cap with plastic flip-off (Box of 1's)
RxVAT-exempt
Glenmark Generics S.A.Argentine Republic
Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Limited
DRP-8102
Mar 6, 2037
OxzaritineOxaliplatin
2 mg/ mL (50 mg/ 25 mL) Concentrate Solution for IV InfusionUSP Type I Amber glass vial with bromobutyl rubber stopper and green flip-off seal x 25 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Oncotine Pharmaceutical Products DistributionImporter: AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-11973-01
May 26, 2027
PlatinoxOxaliplatin
100 mg Lyophilized Powder For Injection (I.V. Infusion)100 mL-capacity USP Type I clear and colorless glass vial with gray bromobutyl rubber stopper and aluminum seal with blue plastic flip-off cap (box of vial)
RxVAT-exempt
Korea United Pharm. Inc.Korea
Qualimed Pharma, Inc.
DR-XY47656
Jan 7, 2027
PlatinoxOxaliplatin
50 mg Lyophilized Powder for IV InfusionClear, colorless glass vial Box of 1's
RxVAT-exempt
Korea United Pharm., Inc.Republic of Korea
Qualimed Pharma Inc.
DR-XY35406
Feb 4, 2029
PlatixelOxaliplatin
5mg/mL Concentrate for Solution For I.V. Infusion20 mL-capacity Type I colorless glass vial with teflon chlorobutyl rubber stopper and aluminum cap (Box of 1 vial x 10 mL; Box of 1 vial x 20 mL)
RxVAT-exempt
Sichuan Huiyu Pharmaceutical Company LimitedChina
Oncolife Corporation
DR-XY48273
Aug 15, 2027
PlaxatinOxaliplatin
50 mg Lyophilized Powder for Injection for I.V. InfusionType I medium boron silicon glass tube-type vial sealed with pharmaceutical bromo butyl rubber stopper (Box of 1's)
RxVAT-exempt
Jari Pharmaceutical Co., Ltd.People's Republic of China
AMB HK ENTERPRISES INC.
DRP-10590
Oct 20, 2031
RextaOxaliplatin
5 mg/mL (100 mg / 20 mL) Concentrate Solution for I.V. Infusion20 mL (net content) Type 1 clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum seal with white polypropylene flip-off cap (Box of 1's)
RxVAT-exempt
PT. Global Onkolab FarmaIndonesia
Globo Asiatico Enterprises, Inc.Trader: Kalbe International Pte. Ltd.
DR-XY48686
Mar 31, 2031
RextaOxaliplatin
5 mg/mL (50 mg/10 mL) Concentrate Solution for I.V. Infusion10mL (net content) Type 1 clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum seal with white polypropylene flip-off cap (Box of 1's)
RxVAT-exempt
PT Global Onkolab FarmaIndonesia
Globo Asiatico Enterprises, Inc.Trader: Kalbe International Pte. Ltd.
DR-XY48687
Mar 31, 2031
Staloxa-100Oxaliplatin
2 mg/mL (100 mg/50 mL) Concentrate Solution for IV Infusion50 mL-capacity USP Type I Amber Moulded Glass Vial x 50 mL with bromobutyl rubber stopper and green flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Multi Product Line Pharma, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8888
Jul 2, 2030
Staloxa-50Oxaliplatin
2 mg/mL (50 mg/25 mL) Concentrate Solution for IV Infusion30 mL-capacity USP Type I Amber Moulded Glass Vial x 25 mL with bromobutyl rubber stopper and green flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Multi Product Line Pharma, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8887
Jul 2, 2030
UketOxaliplatin
2 mg/mL Concentrate Solution for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 50 mL (Box of 1’s)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11225-03
Feb 15, 2027
UketOxaliplatin
2 mg/mL Concentrate Solution for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x 25 mL (Box of 1’s)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11225-04
Feb 15, 2027
Unioxali 100Oxaliplatin
2 mg/mL (100 mg/50 mL) Concentrate Solution for IV InfusionUSP Type I Amber glass vial with bromobutyl rubber stopper and green flip-off seal x 50 mL (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
Pharma 518, Inc.Importer: AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-11974
May 26, 2032
Unioxali 50Oxaliplatin
2 mg/mL (50 mg/25 mL) Concentrate Solution for IV InfusionUSP Type I Amber glass vial with bromobutyl rubber stopper and green flip-off seal x 25 mL (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
Pharma 518, Inc.Importer: AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-11973
May 26, 2037
Vexplatin VE-100Oxaliplatin
5 mg/mL (100 mg/20 mL) Solution for Injection (IV Infusion)Type I Amber Colored Glass Vial with Bromobutyl Flurocoated Rubber Stopper and Aluminum PP Flip-Off Cap x 20 mL (Box of 1’s)
RxVAT-exempt
Venus Remedies LimitedIndia
VE Pharma, Inc.Trader: Vexxa Lifesciences Pvt. Ltd
DRP-10856
Dec 9, 2031
Vexplatin Ve-50Oxaliplatin
5 mg/mL (50 mg/10 mL) Solution for Injection (IV Infusion)Type I Amber Colored Glass Vial with Bromobutyl Flurocoated Rubber Stopper and Aluminum PP Flip Off Cap x 10 mL (Box of 1’s)
RxVAT-exempt
Venus Remedies LimitedIndia
VE Pharma, Inc.Trader: Vexxa Lifesciences Pvt. Ltd
DRP-10857
Dec 9, 2031
Vexplatin-100Oxaliplatin
2 mg/mL ( 100 mg/50 mL) Solution for I.V InfusionUSP Type I Amber Glass Vial x 50 mL (50 mL as Net Content) (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY44380
Mar 26, 2030
Vexplatin-50Oxaliplatin
2 mg/mL (50 mg/25 mL) Solution for I.V. InfusionUSP Type I Amber Glass Vial x 30 mL (25 mL as net content) Box of 1’s
RxVAT-exempt
ADMAC LifesciencesIndia
VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY44379
Mar 26, 2030
XalipatOxaliplatin
2 mg/mL (100 mg/50 mL) Solution for Injection (iv)Type I Amber Moulded Glass Vial x 50 mL (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Medethix, Inc.
DRP-5174
Feb 13, 2029
Zildox 50Oxaliplatin
50 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial (Box of 1's)
RxVAT-exempt
Naprod Lifesciences Pvt. Ltd.India
Multicare Pharmaceuticals Phils. Inc.
DRP-2905
Aug 24, 2032

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Injection: 50 mg (5 mg/mL), 100 mg (5 mg/mL) or 200 mg (5 mg/mL) clear, colorless solution in a single-dose vial. Injection: 50 mg (5 mg/mL), 100 mg (5 mg/mL) or 200 mg (5 mg/mL) in a single-dose vial (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Peripheral Sensory Neuropathy: Acute and delayed neuropathy can occur. Avoid topical application of ice. Reduce the dose or permanently discontinue oxaliplatin as recommended. (5.2)
  • Severe Myelosuppression: Delay oxaliplatin until neutrophils are greater than or equal to 1.5 × 10 9 /L and platelets are greater than or equal to 75 × 10 9 /L. Withhold oxaliplatin for sepsis or septic shock. Dose reduce after recovery from grade 4 neutropenia, febrile neutropenia, or grade 3 to 4 thrombocytopenia as recommended. (5.3)
  • Posterior Reversible Encephalopathy Syndrome (PRES): Permanently discontinue oxaliplatin in patients who develop PRES. (5.4)
  • Pulmonary Toxicity: Withhold oxaliplatin until investigation excludes interstitial lung disease or pulmonary fibrosis. (5.5)
  • Hepatotoxicity: Monitor liver function tests at baseline, before each subsequent cycle, and as clinically indicated. (5.6)
  • QT Interval Prolongation: Avoid in patients with congenital long QT syndrome. Monitor electrocardiograms in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Correct electrolyte abnormalities prior to initiating oxaliplatin and periodically during treatment. (5.7)
  • Rhabdomyolysis: Permanently discontinue oxaliplatin if rhabdomyolysis occurs. (5.8)
  • Hemorrhage: Increase frequency …
5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions Serious and fatal hypersensitivity reactions, including anaphylaxis, can occur with oxaliplatin within minutes of administration and during any cycle. Grade 3 to 4 hypersensitivity reactions, including anaphylaxis, occurred in 2% to 3% of patients with colon cancer who received oxaliplatin.

Hypersensitivity reactions, including rash, urticaria, erythema, pruritus, and rarely, bronchospasm and hypotension, were similar in nature and severity to those reported with other platinum-based drugs. Oxaliplatin is contraindicated in patients with hypersensitivity reactions to platinum-based drugs [see Contraindications (4)].

Immediately and permanently discontinue oxaliplatin for hypersensitivity reactions and administer appropriate treatment for management of hypersensitivity reactions.

5.2 Peripheral Sensory Neuropathy

5.2 Peripheral Sensory Neuropathy Oxaliplatin can cause acute and delayed neuropathy. Reduce the dose or permanently discontinue oxaliplatin for persistent neurosensory reactions based on the severity of the adverse reaction [see Dosage and Administration (2.2)]. Acute Neuropathy Acute neuropathy typically presents as a reversible, primarily peripheral sensory neuropathy that occurs within hours or 2 days following a dose, resolves within 14 days, and frequently recurs with further dosing.

The symptoms can be precipitated or exacerbated by exposure to cold temperature or cold objects and they usually present as transient paresthesia, dysesthesia and hypoesthesia in the hands, feet, perioral area, or throat. Jaw spasm, abnormal tongue sensation, dysarthria, eye pain, and a feeling of chest pressure have also been observed.

The acute, reversible pattern of sensory neuropathy was observed in about 56% of patients who received oxaliplatin with fluorouracil/leucovorin. In any individual cycle, acute neuropathy occurred in approximately 30% of patients. For grade 3 peripheral sensory neuropathy, the median time to onset was 9 cycles for adjuvant treatment and 6 cycles for previously treated advanced colorectal cancer.

An acute syndrome of pharyngolaryngeal dysesthesia occurred in 1% to 2% (grade 3 to 4) of patients previously untreated for advanced colorectal cancer. Subjective sensations of dysphagia or dyspnea, without any laryngospasm or bronchospasm (no stridor or wheezing) occurred in patients previously treated for advanced colorectal cancer.

Avoid topical application of ice for mucositis prophylaxis or other conditions, because cold temperature can exacerbate acute neurological symptoms. Delayed Neuropathy Delayed neuropathy typically presents as a persistent (greater than 14 days), primarily peripheral sensory neuropathy that is usually characterized by paresthesias, dysesthesias, and hypoesthesias, but may also include deficits in proprioception that can interfere with daily activities (e.g., writing, buttoning, swallowing, and difficulty walking from impaired proprioception).

These forms of neuropathy occurred in 48% of patients receiving oxaliplatin. Delayed neuropathy can occur without any prior acute neuropathy. Most patients (80%) who developed grade 3 persistent neuropathy progressed from prior grade 1 or 2 reactions. These symptoms may improve in some patients upon discontinuation of oxaliplatin.

Adjuvant treatment In the adjuvant treatment trial, neuropathy was graded using NCI CTC, version 1 as summarized in Table 3. Table 3: Grading for Neuropathy in Adjuvant Treatment Trial Grade Definition 0 No change or none 1 Mild paresthesias, loss of deep tendon reflexes 2 Mild or moderate objective sensory loss, moderate paresthesias 3 Severe objective sensory loss or paresthesias that interfere with function 4 Not applicable Peripheral sensory neuropathy occurred in 92% of patients (all grades), including 13% of patients (grade 3) who received oxaliplatin with fluorouracil/leucovorin.

At the 28-day follow-up after the last treatment cycle, 60% of patients had any grade (grade 1=40%, grade 2=16%, grade 3=5%) peripheral sensory neuropathy, decreasing to 39% at 6 months of follow-up (grade 1=31%, grade 2=7%, grade 3=1%) and 21% at 18 months of follow-up (grade 1=17%, grade 2=3%, grade 3=1%). Advanced colorectal cancer In the advanced colorectal cancer trials, neuropathy was graded using the neurotoxicity scale summarized in Table 4.

Table 4: Grading for Neuropathy in Advanced Colorectal Cancer Trials Grade Definition 1 Resolved and did not interfere with functioning 2 Interfered with function but not daily activities 3 Pain or functional impairment that interfered with daily activities 4 Persistent impairment that is disabling or life-threatening Neuropathy occurred in 82% (all grades) of patients previously untreated for advanced colorectal cancer, including 19% grade 3 to 4; and in 74% (all grades) of patients previously treated for advanced colorectal cancer, including 7% grade 3 to 4.

5.3 Severe Myelosuppression

5.3 Severe Myelosuppression Grade 3 or 4 neutropenia occurred in 41% to 44% of patients with colorectal cancer who received oxaliplatin with fluorouracil/leucovorin. Sepsis, neutropenic sepsis and septic shock, including fatal outcomes, occurred in patients who received oxaliplatin [see Adverse Reactions (6.1, 6.2)]. Grade 3 or 4 thrombocytopenia occurred in 2% to 5% of patients with colorectal cancer who received oxaliplatin with fluorouracil/leucovorin.

Monitor complete blood cell count at baseline, before each subsequent cycle and as clinically indicated. Delay oxaliplatin until neutrophils are greater than or equal to 1.5 × 10 9 /L and platelets are greater than or equal to 75 × 10 9 /L. Withhold oxaliplatin for sepsis or septic shock. Dose reduce oxaliplatin after recovery from grade 4 neutropenia, febrile neutropenia or grade 3 to 4 thrombocytopenia as recommended [see Dosage and Administration (2.2)].

5.4 Posterior Reversible Encephalopathy Syndrome

5.4 Posterior Reversible Encephalopathy Syndrome PRES occurred in less than 0.1% of patients across clinical trials [see Adverse Reactions (6.1)]. Signs and symptoms of PRES can include headache, altered mental functioning, seizures, abnormal vision from blurriness to blindness, associated or not with hypertension. Confirm the diagnosis of PRES with magnetic resonance imaging.

Permanently discontinue oxaliplatin in patients who develop PRES.

5.5 Pulmonary Toxicity

5.5 Pulmonary Toxicity Oxaliplatin has been associated with pulmonary fibrosis (less than 1% of patients), which may be fatal [see Adverse Reactions (6.1)]. In the adjuvant treatment trial, the combined incidence of cough and dyspnea was 7.4% (any grade), including less than 1% (grade 3) in the oxaliplatin arm. One patient died from eosinophilic pneumonia in the oxaliplatin arm.

In the previously untreated advanced colorectal cancer trial, the combined incidence of cough, dyspnea and hypoxia was 43% (any grade), including 7% (grade 3 to 4) in the oxaliplatin with fluorouracil/leucovorin arm. In case of unexplained respiratory symptoms, such as non-productive cough, dyspnea, crackles, or radiological pulmonary infiltrates, withhold oxaliplatin until further pulmonary investigation excludes interstitial lung disease or pulmonary fibrosis.

Permanently discontinue oxaliplatin for confirmed interstitial lung disease or pulmonary fibrosis.

5.6 Hepatotoxicity

5.6 Hepatotoxicity In the adjuvant treatment trial, increased transaminases (57% vs 34%) and alkaline phosphatase (42% vs 20%) occurred more commonly in the oxaliplatin arm than in the fluorouracil/leucovorin arm [see Adverse Reactions (6.1)]. The incidence of increased bilirubin was similar on both arms. Changes noted on liver biopsies include: peliosis, nodular regenerative hyperplasia or sinusoidal alterations, perisinusoidal fibrosis, and veno-occlusive lesions.

Consider evaluating patients who develop abnormal liver tests or portal hypertension, which cannot be explained by liver metastases, for hepatic vascular disorders. Monitor liver function tests at baseline, before each subsequent cycle, and as clinically indicated.

5.7 QT Interval Prolongation and Ventricular Arrhythmias

5.7 QT Interval Prolongation and Ventricular Arrhythmias QT prolongation and ventricular arrhythmias, including fatal torsade de pointes, have been reported with oxaliplatin [see Adverse Reactions (6.2)]. Avoid oxaliplatin in patients with congenital long QT syndrome. Monitor electrocardiograms (ECG) in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities and in patients taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics [see Drug Interactions (7.1)].

Monitor and correct electrolyte abnormalities prior to initiating oxaliplatin and periodically during treatment.

5.8 Rhabdomyolysis

5.8 Rhabdomyolysis Rhabdomyolysis, including fatal cases, has been reported with oxaliplatin [see Adverse Reactions (6.2)]. Permanently discontinue oxaliplatin for any signs or symptoms of rhabdomyolysis.

5.9 Hemorrhage

5.9 Hemorrhage The incidence of hemorrhage in clinical trials was higher on the oxaliplatin combination arm compared to the fluorouracil/leucovorin arm. These reactions included gastrointestinal bleeding, hematuria, and epistaxis. In the adjuvant treatment trial, 2 patients died from intracerebral hemorrhage [see Adverse Reactions (6.1)].

Prolonged prothrombin time and INR occasionally associated with hemorrhage have been reported in patients who received oxaliplatin with fluorouracil/leucovorin while on anticoagulants [see Adverse Reactions (6.2)]. Increase frequency of monitoring in patients who are receiving oxaliplatin with fluorouracil/leucovorin and oral anticoagulants [see Drug Interactions (7.3)].

Thrombocytopenia and immune-mediated thrombocytopenia have been observed with oxaliplatin. Rapid onset of thrombocytopenia and greater risk of bleeding have been observed in immune-mediated thrombocytopenia. In this case, consider discontinuing oxaliplatin.

5.10 Embryo-Fetal Toxicity

5.10 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, oxaliplatin can cause fetal harm when administered to a pregnant woman. The available human data do not establish the presence or absence of major birth defects or miscarriage related to the use of oxaliplatin. Reproductive toxicity studies demonstrated adverse effects on embryo-fetal development in rats at maternal doses that were below the recommended human dose based on body surface area.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with oxaliplatin and for 9 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with oxaliplatin and for 6 months after the final dose [see Use in Specific Populations (8.1, 8.3)].

Drug interactions

Drug interactions (US label) US FDA label
7.1 Drugs

7.1 Drugs that Prolong the QT Interval QT interval prolongation and ventricular arrhythmias can occur with oxaliplatin [see Warnings and Precautions (5.7)]. Avoid coadministration of oxaliplatin with medicinal products with a known potential to prolong the QT interval.

7.2 Use with Nephrotoxic Products

7.2 Use with Nephrotoxic Products Because platinum-containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds [see Clinical Pharmacology (12.3)]. Avoid coadministration of oxaliplatin with medicinal products known to cause nephrotoxicity.

7.3 Use with Anticoagulants

7.3 Use with Anticoagulants Prolonged prothrombin time and INR occasionally associated with hemorrhage have been reported in patients who received oxaliplatin with fluorouracil/leucovorin while on anticoagulants [see Warnings and Precautions (5.9), Adverse Reactions (6.2)]. Increase frequency of monitoring in patients who are receiving oxaliplatin with fluorouracil/leucovorin and oral anticoagulants.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Peripheral Sensory Neuropathy [see Warnings and Precautions (5.2)] Severe Myelosuppression [see Warnings and Precautions (5.3)] Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.4)] Pulmonary Toxicity [see Warnings and Precautions (5.5)] Hepatotoxicity [see Warnings and Precautions (5.6)] QT Interval Prolongation and Ventricular Arrhythmias [see Warnings and Precautions (5.7)] Rhabdomyolysis [see Warnings and Precautions (5.8)] Hemorrhage [see Warnings and Precautions (5.9)] Most common adverse reactions (incidence greater than or equal to 40%) were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue, and stomatitis. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Gland Pharma at 864-879-9994 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. More than 1100 patients with stage II or III colon cancer and more than 4,000 patients with advanced colorectal cancer were treated in trials with oxaliplatin.

The most common adverse reactions in patients with stage II or III colon cancer receiving adjuvant treatment were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue and stomatitis. The most common adverse reactions in previously untreated and treated patients with advanced colorectal cancer were peripheral sensory neuropathies, fatigue, neutropenia, nausea, emesis, and diarrhea.

Adjuvant Treatment The safety of oxaliplatin in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in patients with stage II or III colon cancer, who had undergone complete resection of the primary tumor in the adjuvant treatment trial [see Clinical Studies (14.1)]. Fatal adverse reactions in patients who received oxaliplatin in the combination arm included sepsis/neutropenic sepsis (n=3), intracerebral hemorrhage (n=2), and eosinophilic pneumonia (n=1).

Thromboembolic events occurred in 6% (grade 3 to 4, 1.2%) of patients in the oxaliplatin arm. Grade 3 or 4 adverse reactions occurred in 70% of patients in the oxaliplatin arm. Grade 3 to 4 gastrointestinal bleeding occurred in 0.2% of patients. Febrile neutropenia occurred in 0.7% and documented infection with concomitant grade 3 to 4 neutropenia occurred in 1.1%.

Discontinuation due to an adverse reaction occurred in 15% of the patients in the oxaliplatin arm. Tables 5, 6, and 7 summarize the adverse reactions reported in patients with colon cancer receiving adjuvant treatment. Table 5: Adverse Reactions Reported in Patients with Colon Cancer Receiving Adjuvant Treatment (greater than or equal to 5% of all patients and with greater than or equal to 1% grade 3 to 4) Adverse Reaction* Oxaliplatin + FU/LV N=1108 FU/LV N=1111 All Grades (%) Grade 3 to 4 (%) All Grades (%) Grade 3 to 4 (%) Neurology Peripheral Sensory Neuropathy 92 12 16 <1 Gastrointestinal Nausea 74 5 61 2 Diarrhea 56 11 48 7 Vomiting 47 6 24 1 Stomatitis 42 3 40 2 Anorexia 13 1 8 <1 Constitutional Symptoms/Pain Fatigue 44 4 38 1 Abdominal Pain 18 1 17 2 Dermatology/Skin Skin Disorder 32 2 36 2 Injection Site Reaction † 11 3 10 3 Fever/Infection Fever 27 1 12 1 Infection 25 4 25 3 Allergy/Immunology Allergic Reaction 10 3 2 <1 * Event coded in WHO-ART dictionary † Includes thrombosis related to the catheter Table 6: Adverse Reactions Reported in Patients with Colon Cancer Receiving Adjuvant Treatment (greater than or equal to 5% of all patients but with less than 1% grade 3 to 4) Adverse Reaction* Oxaliplatin + FU/LV N=1108 FU/LV N=1111 All Grades (%) All Grades (%) Dermatology/Skin Alopecia † 30 28 Gastrointestinal Constipation 22 19 Taste Perversion 12 8 Dyspepsia 8 5 Constitutional Symptoms/Pain/Ocular/Visual Epistaxis 16 12 Weight Increase 10 10 Conjunctivitis 9 15 Headache 7 5 Dyspnea 5 3 Pain 5 5 Abnormal Lacrimation 4 12 Neurology Sensory Disturbance 8 1 Allergy/Immunology Rhinitis 6 8 * Event coded in WHO-ART dictionary † No complete alopecia was reported In females, the following grade 3 to 4 adverse reactions were more frequent: diarrhea, fatigue, neutropenia, nausea, and vomiting.

In patients greater than or equal to 65 years old, the incidence of grade 3 to 4 diarrhea and neutropenia was higher than in younger adults. Clinically relevant adverse reactions were reported in greater than or equal to 2% and less than 5% of the patients in the oxaliplatin arm (listed in decreasing order of frequency) were pain, leukopenia, weight loss, and cough.

Table 7: Laboratory-Related Adverse Reactions Occurring in ≥5% of Patients with Colon Cancer Receiving Adjuvant Treatment Laboratory-Related Adverse Reaction Oxaliplatin with FU/LV N=1108 FU/LV N=1111 All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) Hematology Neutropenia 79 41 40 5 Thrombocytopenia 77 2 19 <1 Anemia 76 1 67 <1 Hepatic Increased Transaminases 57 2 34 1 Increased Alkaline Phosphatase 42 <1 20 <1 Hyperbilirubinemia 20 4 20 5 Previously Untreated Advanced Colorectal Cancer The safety of oxaliplatin in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in a randomized trial of patients with previously untreated advanced colorectal cancer [see Clinical Studies (14.2)]. The adverse reaction profile in this trial was similar to that seen in other trials.

Tables 8, 9, and 10 summarize the adverse reactions reported in the previously untreated advanced colorectal cancer trial. Table 8: Adverse Reactions Reported in Patients in the Previously Untreated Advanced Colorectal Cancer Clinical Trial (greater than or equal to 5% of all patients and with greater than or equal to 1% grade 3 to 4) Adverse Reaction* Oxaliplatin + FU/LV N=259 Irinotecan + FU/LV N=256 Oxaliplatin + Irinotecan N=258 All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) Neurology Neuropathy 82 19 18 2 69 7 Paresthesias 77 18 16 2 62 6 Pharyngo-laryngeal Dysesthesias 38 2 1 0 28 1 Neuro-sensory 12 1 2 0 9 1 Neuro NOS † 1 0 1 0 1 0 Gastrointestinal Nausea 71 6 67 15 83 19 Diarrhea 56 12 65 29 76 25 Vomiting 41 4 43 13 64 23 Stomatitis 38 0 25 1 19 1 Anorexia 35 2 25 4 27 5 Constipation 32 4 27 2 21 2 Diarrhea-colostomy 13 2 16 7 16 3 Gastrointestinal NOS † 5 2 4 2 3 2 Constitutional Symptoms/Pain/Ocular/Visual Fatigue 70 7 58 11 66 16 Abdominal Pain 29 8 31 7 39 10 Myalgia 14 2 6 0 9 2 Pain 7 1 5 1 6 1 Abnormal Vision 5 0 2 1 6 1 Neuralgia 5 0 0 0 2 1 Pulmonary Cough 35 1 25 2 17 1 Dyspnea 18 7 14 3 11 2 Hiccups 5 1 2 0 3 2 Hepatic/Metabolic/Laboratory/Renal Hyperglycemia 14 2 11 3 12 3 Hypokalemia 11 3 7 4 6 2 Dehydration 9 5 16 11 14 7 Hypoalbuminemia 8 0 5 2 9 1 Hyponatremia 8 2 7 4 4 1 Urinary Frequency 5 1 2 1 3 1 Hematology/Infection Infection Normal ANC ‡ 10 4 5 1 7 2 Infection Low ANC ‡ 8 8 12 11 9 8 Lymphopenia 6 2 4 1 5 2 Febrile Neutropenia 4 4 15 14 12 11 Dermatology/Skin Hand/Foot Syndrome 7 1 2 1 1 0 Injection Site Reaction 6 0 1 0 4 1 Cardiovascular Thrombosis 6 5 6 6 3 3 Hypotension 5 3 6 3 4 3 * Event coded in WHO-ART dictionary † Not otherwise specified ‡ Absolute neutrophil count Table 9: Adverse Reactions Reported in Patients in the Previously Untreated Advanced Colorectal Cancer Clinical Trial (greater than or equal to 5% of all patients but with less than 1% grade 3 to 4) Adverse Reaction* Oxaliplatin + FU/LV N=259 Irinotecan + FU/LV N=256 Oxaliplatin + Irinotecan N=258 All Grades (%) All Grades (%) All Grades (%) Dermatology/Skin Alopecia † 38 44 67 Flushing 7 2 5 Pruritus 6 4 2 Dry Skin 6 2 5 Hematology/Infection Fever Normal ANC ‡ 16 9 9 Cardiovascular Edema 15 13 10 Gastrointestinal Taste Perversion 14 6 8 Dyspepsia 12 7 5 Flatulence 9 6 5 Mouth Dryness 5 2 3 Constitutional Symptoms/Pain/Ocular/Visual Headache 13 6 9 Weight Loss 11 9 11 Epistaxis 10 2 2 Tearing 9 1 2 Rigors 8 2 7 Dysphasia 5 3 3 Sweating 5 6 12 Arthralgia 5 5 8 Neurology Insomnia 13 9 11 Depression 9 5 7 Dizziness 8 6 10 Anxiety 5 2 6 Allergy/Immunology Rash 11 4 7 Rhinitis Allergic 10 6 6 Hepatic/Metabolic/Laboratory/Renal Hypocalcemia 7 5 4 Elevated Creatinine 4 4 5 * Event coded in WHO-ART dictionary † No complete alopecia was reported ‡ Absolute neutrophil count Clinically relevant adverse reactions that occurred in greater than or equal to 2% and less than 5% of the patients in the oxaliplatin and fluorouracil/leucovorin combination arm (listed in decreasing order of frequency) were: metabolic, pneumonitis, catheter infection, vertigo, prothrombin time, pulmonary, rectal bleeding, dysuria, nail changes, chest pain, rectal pain, syncope, hypertension, hypoxia, unknown infection, bone pain, pigmentation changes, and urticaria.

Table 10: Laboratory-Related Adverse Reactions Occurring in ≥5% of Patients in the Previously Untreated Advanced Colorectal Cancer Trial Laboratory-Related Adverse Reaction Oxaliplatin and FU/LV N=259 Irinotecan and FU/LV N=256 Oxaliplatin and Irinotecan N=258 All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) Hematology Leukopenia 85 20 84 23 76 24 Neutropenia 81 53 77 44 71 36 Thrombocytopenia 71 5 26 2 44 4 Anemia 27 3 28 4 25 3 Hepatic Increased AST* 17 1 2 1 11 1 Increased Alkaline Phosphatase 16 0 8 0 14 2 Hyperbilirubinemia 6 1 3 1 3 2 Increased ALT † 6 1 2 0 5 2 * Aspartate transaminase † Alanine transaminase Previously Treated Advanced Colorectal Cancer The safety of oxaliplatin in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in a randomized trial in patients with refractory and relapsed colorectal cancer [see Clinical Studies (14.3)]. The adverse reaction profile in this trial was similar to that seen in other trials.

Three patients who received oxaliplatin in the combination arm experienced fatal adverse reactions: gastrointestinal bleeding and dehydration. Grade 3 and 4 neutropenia were reported in 27% and 17% of patients, respectively, in the oxaliplatin with fluorouracil/leucovorin combination arm. Grade 3 to 4 increased serum creatinine occurred in 1% of patients in the oxaliplatin with combination fluorouracil/leucovorin arm.

Thirteen percent of patients in the oxaliplatin with fluorouracil/leucovorin combination arm discontinued treatment; the most frequent reasons were gastrointestinal adverse reactions, hematologic adverse reactions and neuropathies. Tables 11, 12, and 13 summarize the adverse reactions reported in the previously treated advanced colorectal cancer trial.

Table 11: Adverse Reactions Reported in Patients in the Previously Treated Advanced Colorectal Cancer Trial (greater than or equal to 5% of all patients and with greater than or equal to 1% grade 3 to 4) Adverse Reaction* Oxaliplatin + FU/LV N=150 Oxaliplatin N=153 FU/LV N=142 All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) Neurology Neuropathy 74 7 76 7 17 0 Acute 56 2 65 5 10 0 Persistent 48 6 43 3 9 0 Constitutional Symptoms/Pain Fatigue 68 7 61 9 52 6 Back Pain 19 3 11 0 16 4 Pain 15 2 14 3 9 3 Gastrointestinal Diarrhea 67 11 46 4 44 3 Nausea 65 11 64 4 59 4 Vomiting 40 9 37 4 27 4 Stomatitis 37 3 14 0 32 3 Abdominal Pain 33 4 31 7 31 5 Anorexia 29 3 20 2 20 1 Gastroesophageal Reflux 5 2 1 0 3 0 Hematology/Infection Fever 29 1 25 1 23 1 Febrile Neutropenia 6 6 0 0 1 1 Cardiovascular Dyspnea 20 4 13 7 11 2 Coughing 19 1 11 0 9 0 Edema 15 1 10 1 13 1 Thromboembolism 9 8 2 1 4 2 Chest Pain 8 1 5 1 4 1 Dermatology/Skin Injection Site Reaction 10 3 9 0 5 1 Hepatic/Metabolic/Laboratory/Renal Hypokalemia 9 4 3 2 3 1 Dehydration 8 3 5 3 6 4 * Event coded in WHO-ART dictionary Table 12: Adverse Reactions Reported in Patients in the Previously Treated Advanced Colorectal Cancer Clinical Trial (greater than or equal to 5% of all patients but with less than 1% grade 3 to 4) Adverse Reaction* Oxaliplatin + FU/LV N=150 Oxaliplatin N=153 FU/LV N=142 All Grades (%) All Grades (%) All Grades (%) Gastrointestinal Constipation 32 31 23 Dyspepsia 14 7 10 Taste Perversion 13 5 1 Mucositis 7 2 10 Flatulence 5 3 6 Constitutional Symptoms/Pain/Ocular/Visual Headache 17 13 8 Arthralgia 10 7 10 Epistaxis 9 2 1 Abnormal Lacrimation 7 1 6 Rigors 7 9 6 Allergy/Immunology Rhinitis 15 6 4 Allergic Reaction 10 3 1 Rash 9 5 5 Neurology Dizziness 13 7 8 Insomnia 9 11 4 Dermatology/Skin Hand-Foot Syndrome 11 1 13 Flushing 10 3 2 Alopecia † 7 3 3 Pulmonary Upper Respiratory Tract Infection 10 7 4 Pharyngitis 9 2 10 Cardiovascular Peripheral Edema 10 5 11 Hepatic/Metabolic/Laboratory/Renal Hematuria 6 0 4 Dysuria 6 1 1 * Event coded in WHO-ART dictionary † No complete alopecia was reported Clinically relevant adverse reactions in greater than or equal to 2% and less than 5% of the patients in the oxaliplatin and fluorouracil/leucovorin combination arm (listed in decreasing order of frequency) were: anxiety, myalgia, erythematous rash, increased sweating, conjunctivitis, weight decrease, dry mouth, rectal hemorrhage, depression, ataxia, ascites, hemorrhoids, muscle weakness, nervousness, tachycardia, abnormal micturition frequency, dry skin, pruritus, hemoptysis, purpura, vaginal hemorrhage, melena, somnolence, pneumonia, proctitis, involuntary muscle contractions, intestinal obstruction, gingivitis, tenesmus, hot flashes, enlarged abdomen, and urinary incontinence. Table 13: Laboratory-Related Adverse Reactions Occurring in ≥5% of Patients with Previously Treated Advanced Colorectal Cancer Laboratory-Related Adverse Reaction Oxaliplatin and FU/LV N=150 Oxaliplatin N=153 FU/LV N=142 All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) Hematology Anemia 81 2 64 1 68 2 Leukopenia 76 19 13 0 34 1 Neutropenia 73 44 7 0 25 5 Thrombocytopenia 64 4 30 3 20 0 Hepatic Increased ALT * 31 0 36 1 28 3 Increased AST † 47 0 54 4 39 2 Increased Bilirubin 13 1 13 5 22 6 * Alanine transaminase † Aspartate transaminase Additional Adverse Reactions The following adverse reactions were observed across clinical trials.

Intravenous site reactions Injection site reaction, including redness, swelling, and pain, can occur with oxaliplatin. In some cases, skin necrosis has occurred with extravasation. PRES PRES occurred in less than 0.1% of patients. Pulmonary fibrosis and interstitial lung disease Pulmonary fibrosis, which may be fatal, occurred in less than 1% of patients.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of oxaliplatin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

General: angioedema, anaphylactic shock Cardiovascular: QT prolongation leading to ventricular arrhythmias, including fatal torsade de pointes; bradyarrhythmia Neurological: loss of deep tendon reflexes, dysarthria, Lhermitte’s sign, cranial nerve palsies, fasciculations, convulsion Hearing and vestibular system: deafness Infections: septic shock, including fatal outcomes Infusion-related reactions and hypersensitivity reactions: laryngospasm Hepatic and gastrointestinal: severe diarrhea/vomiting resulting in hypokalemia, colitis (including Clostridium difficile diarrhea), metabolic acidosis, ileus, intestinal obstruction, pancreatitis, sinusoidal obstruction syndrome, perisinusoidal fibrosis which rarely may progress, focal nodular hyperplasia, esophagitis Musculoskeletal and connective tissue: rhabdomyolysis, including fatal outcomes Platelet, bleeding, and clotting disorders: immuno-allergic thrombocytopenia, prolonged prothrombin time and INR in patients receiving anticoagulants Blood disorders: secondary leukemia Red blood cell: hemolytic uremic syndrome, immuno-allergic hemolytic anemia Renal: acute tubular necrosis, acute interstitial nephritis, acute renal failure Respiratory: interstitial lung diseases (sometimes fatal) and pneumonia (including fatal outcomes) Vision: decrease of visual acuity, visual field disturbance, optic neuritis and transient vision loss (reversible following treatment discontinuation) Injury, poisoning, and procedural complications: fall-related injuries

Adverse reaction frequency tables (US label) US FDA label
Adverse Reaction* Oxaliplatin + FU/LV N=1108 FU/LV N=1111
All Grades (%) Grade 3 to 4 (%) All Grades (%) Grade 3 to 4 (%)
Neurology
Peripheral Sensory Neuropathy 92 12 16 <1
Gastrointestinal
Nausea 74 5 61 2
Diarrhea 56 11 48 7
Vomiting 47 6 24 1
Stomatitis 42 3 40 2
Anorexia 13 1 8 <1
Constitutional Symptoms/Pain
Fatigue 44 4 38 1
Abdominal Pain 18 1 17 2
Dermatology/Skin
Skin Disorder 32 2 36 2
Injection Site Reaction† 11 3 10 3
Fever/Infection
Fever 27 1 12 1
Infection 25 4 25 3
Allergy/Immunology
Allergic Reaction 10 3 2 <1
Adverse Reaction* Oxaliplatin + FU/LV N=1108 FU/LV N=1111
All Grades (%) All Grades (%)
Dermatology/Skin
Alopecia† 30 28
Gastrointestinal
Constipation 22 19
Taste Perversion 12 8
Dyspepsia 8 5
Constitutional Symptoms/Pain/Ocular/Visual
Epistaxis 16 12
Weight Increase 10 10
Conjunctivitis 9 15
Headache 7 5
Dyspnea 5 3
Pain 5 5
Abnormal Lacrimation 4 12
Neurology
Sensory Disturbance 8 1
Allergy/Immunology
Rhinitis 6 8
Laboratory-Related Adverse Reaction Oxaliplatin with FU/LV N=1108 FU/LV N=1111
All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%)
Hematology
Neutropenia 79 41 40 5
Thrombocytopenia 77 2 19 <1
Anemia 76 1 67 <1
Hepatic
Increased Transaminases 57 2 34 1
Increased Alkaline Phosphatase 42 <1 20 <1
Hyperbilirubinemia 20 4 20 5
Adverse Reaction* Oxaliplatin + FU/LV N=259 Irinotecan + FU/LV N=256 Oxaliplatin + Irinotecan N=258
All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%)
Neurology
Neuropathy 82 19 18 2 69 7
Paresthesias 77 18 16 2 62 6
Pharyngo-laryngeal Dysesthesias 38 2 1 0 28 1
Neuro-sensory 12 1 2 0 9 1
Neuro NOS† 1 0 1 0 1 0
Gastrointestinal
Nausea 71 6 67 15 83 19
Diarrhea 56 12 65 29 76 25
Vomiting 41 4 43 13 64 23
Stomatitis 38 0 25 1 19 1
Anorexia 35 2 25 4 27 5
Constipation 32 4 27 2 21 2
Diarrhea-colostomy 13 2 16 7 16 3
Gastrointestinal NOS† 5 2 4 2 3 2
Constitutional Symptoms/Pain/Ocular/Visual
Fatigue 70 7 58 11 66 16
Abdominal Pain 29 8 31 7 39 10
Myalgia 14 2 6 0 9 2
Pain 7 1 5 1 6 1
Abnormal Vision 5 0 2 1 6 1
Neuralgia 5 0 0 0 2 1
Pulmonary
Cough 35 1 25 2 17 1
Dyspnea 18 7 14 3 11 2
Hiccups 5 1 2 0 3 2
Hepatic/Metabolic/Laboratory/Renal
Hyperglycemia 14 2 11 3 12 3
Hypokalemia 11 3 7 4 6 2
Dehydration 9 5 16 11 14 7
Hypoalbuminemia 8 0 5 2 9 1
Hyponatremia 8 2 7 4 4 1
Urinary Frequency 5 1 2 1 3 1
Hematology/Infection
Infection Normal ANC‡ 10 4 5 1 7 2
Infection Low ANC‡ 8 8 12 11 9 8
Lymphopenia 6 2 4 1 5 2
Febrile Neutropenia 4 4 15 14 12 11
Dermatology/Skin
Hand/Foot Syndrome 7 1 2 1 1 0
Injection Site Reaction 6 0 1 0 4 1
Cardiovascular
Thrombosis 6 5 6 6 3 3
Hypotension 5 3 6 3 4 3
Adverse Reaction* Oxaliplatin + FU/LV N=259 Irinotecan + FU/LV N=256 Oxaliplatin + Irinotecan N=258
All Grades (%) All Grades (%) All Grades (%)
Dermatology/Skin
Alopecia† 38 44 67
Flushing 7 2 5
Pruritus 6 4 2
Dry Skin 6 2 5
Hematology/Infection
Fever Normal ANC‡ 16 9 9
Cardiovascular
Edema 15 13 10
Gastrointestinal
Taste Perversion 14 6 8
Dyspepsia 12 7 5
Flatulence 9 6 5
Mouth Dryness 5 2 3
Constitutional Symptoms/Pain/Ocular/Visual
Headache 13 6 9
Weight Loss 11 9 11
Epistaxis 10 2 2
Tearing 9 1 2
Rigors 8 2 7
Dysphasia 5 3 3
Sweating 5 6 12
Arthralgia 5 5 8
Neurology
Insomnia 13 9 11
Depression 9 5 7
Dizziness 8 6 10
Anxiety 5 2 6
Allergy/Immunology
Rash 11 4 7
Rhinitis Allergic 10 6 6
Hepatic/Metabolic/Laboratory/Renal
Hypocalcemia 7 5 4
Elevated Creatinine 4 4 5
Laboratory-Related Adverse Reaction Oxaliplatin and FU/LV N=259 Irinotecan and FU/LV N=256 Oxaliplatin and Irinotecan N=258
All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%)
Hematology
Leukopenia 85 20 84 23 76 24
Neutropenia 81 53 77 44 71 36
Thrombocytopenia 71 5 26 2 44 4
Anemia 27 3 28 4 25 3
Hepatic
Increased AST* 17 1 2 1 11 1
Increased Alkaline Phosphatase 16 0 8 0 14 2
Hyperbilirubinemia 6 1 3 1 3 2
Increased ALT† 6 1 2 0 5 2
Adverse Reaction* Oxaliplatin + FU/LV N=150 Oxaliplatin N=153 FU/LV N=142
All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%)
Neurology
Neuropathy 74 7 76 7 17 0
Acute 56 2 65 5 10 0
Persistent 48 6 43 3 9 0
Constitutional Symptoms/Pain
Fatigue 68 7 61 9 52 6
Back Pain 19 3 11 0 16 4
Pain 15 2 14 3 9 3
Gastrointestinal
Diarrhea 67 11 46 4 44 3
Nausea 65 11 64 4 59 4
Vomiting 40 9 37 4 27 4
Stomatitis 37 3 14 0 32 3
Abdominal Pain 33 4 31 7 31 5
Anorexia 29 3 20 2 20 1
Gastroesophageal Reflux 5 2 1 0 3 0
Hematology/Infection
Fever 29 1 25 1 23 1
Febrile Neutropenia 6 6 0 0 1 1
Cardiovascular
Dyspnea 20 4 13 7 11 2
Coughing 19 1 11 0 9 0
Edema 15 1 10 1 13 1
Thromboembolism 9 8 2 1 4 2
Chest Pain 8 1 5 1 4 1
Dermatology/Skin
Injection Site Reaction 10 3 9 0 5 1
Hepatic/Metabolic/Laboratory/Renal
Hypokalemia 9 4 3 2 3 1
Dehydration 8 3 5 3 6 4
Adverse Reaction* Oxaliplatin + FU/LV N=150 Oxaliplatin N=153 FU/LV N=142
All Grades (%) All Grades (%) All Grades (%)
Gastrointestinal
Constipation 32 31 23
Dyspepsia 14 7 10
Taste Perversion 13 5 1
Mucositis 7 2 10
Flatulence 5 3 6
Constitutional Symptoms/Pain/Ocular/Visual
Headache 17 13 8
Arthralgia 10 7 10
Epistaxis 9 2 1
Abnormal Lacrimation 7 1 6
Rigors 7 9 6
Allergy/Immunology
Rhinitis 15 6 4
Allergic Reaction 10 3 1
Rash 9 5 5
Neurology
Dizziness 13 7 8
Insomnia 9 11 4
Dermatology/Skin
Hand-Foot Syndrome 11 1 13
Flushing 10 3 2
Alopecia† 7 3 3
Pulmonary
Upper Respiratory Tract Infection 10 7 4
Pharyngitis 9 2 10
Cardiovascular
Peripheral Edema 10 5 11
Hepatic/Metabolic/Laboratory/Renal
Hematuria 6 0 4
Dysuria 6 11
Laboratory-Related Adverse Reaction Oxaliplatin and FU/LV N=150 Oxaliplatin N=153 FU/LV N=142
All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%) All Grades (%) Grades 3 to 4 (%)
Hematology
Anemia 81 2 64 1 68 2
Leukopenia 76 19 13 0 34 1
Neutropenia 73 44 7 0 25 5
Thrombocytopenia 64 4 30 3 20 0
Hepatic
Increased ALT* 31 0 36 1 28 3
Increased AST† 47 0 54 4 39 2
Increased Bilirubin 13 1 13 5 22 6

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on its direct interaction with DNA, oxaliplatin can cause fetal harm when administered to a pregnant woman. The available human data do not establish the presence or absence of major birth defects or miscarriage related to the use of oxaliplatin. Reproductive toxicity studies demonstrated adverse effects on embryo-fetal development in rats at maternal doses that were below the recommended human dose based on body surface area (see Data).

Advise a pregnant woman of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal data Pregnant rats were administered oxaliplatin at less than one-tenth the recommended human dose based on body surface area during gestation days (GD) 1 to 5 (preimplantation), GD 6 to 10, or GD 11 to 16 (during organogenesis).

Oxaliplatin caused developmental mortality (increased early resorptions) when administered on days GD 6 to 10 and GD 11 to 16 and adversely affected fetal growth (decreased fetal weight, delayed ossification) when administered on days GD 6 to 10.

Breastfeeding considerations

Lactation (US label) US FDA label

8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating oxaliplatin [see Use in Specific Populations (8.1)]. Contraception Oxaliplatin can cause embryo-fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

Females Advise female patients of reproductive potential to use effective contraception while receiving oxaliplatin and for 9 months after the final dose. Males Based on its mechanism action as a genotoxic drug, advise males with female partners of reproductive potential to use effective contraception while receiving oxaliplatin and for 6 months after the final dose [see Nonclinical Toxicology (13.1)].

Infertility Based on animal studies, oxaliplatin may impair fertility in males and females [see Nonclinical Toxicology (13.1)].

Mechanism of action

12.1 Mechanism of Action Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed.

Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific. In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma.

In combination with fluorouracil, oxaliplatin exhibits in vitro and in vivo antiproliferative activity greater than either compound alone in several tumor models (HT29 [colon], GR [mammary], and L1210 [leukemia]).

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics A pharmacodynamic relationship between platinum ultrafiltrate levels and clinical safety and effectiveness has not been established.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The remaining 85% is rapidly distributed into tissues or eliminated in the urine.

Excretion The major route of platinum elimination is renal excretion.

At five days after a single 2-hour infusion of oxaliplatin, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%.

The renal clearance of ultrafiltrable platinum is significantly correlated with GFR.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The reactive oxaliplatin derivatives are present as a fraction of the unbound platinum in plasma ultrafiltrate. After a single 2-hour intravenous infusion of oxaliplatin at a dose of 85 mg/m 2, pharmacokinetic parameters expressed as ultrafiltrable platinum were Cmax of 0.814 mcg/mL and volume of distribution of 440 L.

Interpatient and intrapatient variability in ultrafiltrable platinum exposure (AUC0-48hr) assessed over 3 cycles was 23% and 6%, respectively. Distribution At the end of a 2-hour infusion of oxaliplatin, approximately 15% of the administered platinum is present in the systemic circulation. The remaining 85% is rapidly distributed into tissues or eliminated in the urine.

The decline of ultrafiltrable platinum levels following oxaliplatin administration is triphasic, including two distribution phases (t 1/2α; 0.43 hours and t 1/2β; 16.8 hours). In patients, plasma protein binding of platinum is irreversible and is greater than 90%. The main binding proteins are albumin and gamma-globulins.

Platinum also binds irreversibly and accumulates (approximately 2-fold) in erythrocytes, where it appears to have no relevant activity. No platinum accumulation was observed in plasma ultrafiltrate following 85 mg/m 2 every two weeks. Elimination The decline of ultrafiltrable platinum concentrations from plasma is characterized by a long terminal elimination phase (t 1/2 γ; 391 hour).

Metabolism Oxaliplatin undergoes rapid and extensive nonenzymatic biotransformation. There is no evidence of cytochrome P450-mediated metabolism in vitro. Up to 17 platinum-containing derivatives have been observed in plasma ultrafiltrate samples from patients, including several cytotoxic species (monochloro DACH platinum, dichloro DACH platinum, and monoaquo and diaquo DACH platinum) and a number of noncytotoxic, conjugated species.

Excretion The major route of platinum elimination is renal excretion. At five days after a single 2-hour infusion of oxaliplatin, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%. Platinum was cleared from plasma at a rate (10 to 17 L/h) that was similar to or exceeded the average human glomerular filtration rate (GFR; 7.5 L/h).

The renal clearance of ultrafiltrable platinum is significantly correlated with GFR. Special Populations Sex There was no significant effect of sex on the clearance of ultrafiltrable platinum. Patients with renal impairment Patients with normal function (CLcr greater than 80 mL/min) and patients with mild (CLcr=50 to 80 mL/min) and moderate (CLcr equal to 30 to 49 mL/min) renal impairment received oxaliplatin 85 mg/m2 and those with severe (CLcr less than 30 mL/min) renal impairment received oxaliplatin 65 mg/m 2.

Mean dose adjusted AUC of unbound platinum was 40%, 95%, and 342% higher for patients with mild, moderate, and severe renal impairment, respectively, compared to patients with normal renal function. Mean dose adjusted Cmax of unbound platinum appeared to be similar among the normal, mild and moderate renal function groups, but was 38% higher in the severe group than in the normal group [see Dosage and Administration (2.3)].

Drug Interaction Studies No pharmacokinetic interaction between oxaliplatin 85 mg/m2 and infusional fluorouracil has been observed in patients treated every 2 weeks, but increases of fluorouracil plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 of oxaliplatin administered every 3 weeks. In vitro platinum was not displaced from plasma proteins by the following medications: erythromycin, salicylate, sodium valproate, granisetron, and paclitaxel.

In vitro oxaliplatin does not inhibit human cytochrome P450 isoenzymes.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Oxaliplatin 5 mg/mL concentrate solution, 10 mL Vial₱1,164.35–₱1,689.00Reference ₱1,475.45per vialDPRI procurement range
Oxaliplatin 5 mg/mL concentrate solution, 20 mL Vial₱1,787.00–₱2,798.00Reference ₱2,725.00per vialDPRI procurement range
Oxaliplatin 50 mg powder Vial₱1,095.00–₱2,998.00Reference ₱1,165.79per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Oxaliplatin
PNF listingInj.: 5 mg/mL concentrate solution, 10 mL and 20 mL vial (IV infusion) powder, 50 mg vial (IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Oxaliplatin · Gland Pharma Limited [US FDA-approved label, version 11, August 24, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6f89dc3-a594-4b5b-8728-272e20c1ecb5
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .